FindTrial
Sign In

Eeffectiveness and safety of Azivudine in the treatment of COVID-19 infection. in the real world, a retrospective, cohort study.

Evaluation of the effectiveness of Azivudine in the treatment of COVID-19 infection. in the real world, a retrospective, cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200066351
Enrollment
Unknown
Registered
2022-12-01
Start date
2022-12-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group Azivudine:N/A
Group Paxlovid:N/A

Sponsors

Xi'an Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Age = 18 years, gender not limited. 2) Positive for novel coronavirus nucleic acid by PCR. 3) The first dose of antiviral drugs for no more than 3 days. 4) Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1) Pregnant women and lactating mothers. 2) severe cardiopulmonary insufficiency. 3) hepatic and renal failure (liver failure and glomerular filtration rate less than 30).

Design outcomes

Primary

MeasureTime frame
mild to moderate;—

Secondary

MeasureTime frame
Nucleic acid convertion time;oxygen therapy;drug side effect;—

Countries

China

Contacts

Public ContactYangHan

Xi'an Chest Hospital

854810572@qq.com18189125501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026